Profile
Sector:
HealthcareCountry:
United StatesIPO:
29 October 2021Website:
http://www.biofrontera-us.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 21:38:46 GMTDividend
Analysts recommendations
Institutional Ownership
BFRI Latest News
Biofrontera Inc. (NASDAQ:BFRI ) Q3 2024 Earnings Conference Call November 14, 2024 10:00 AM ET Company Participants Andrew Barwicki - Investor Relations Hermann Luebbert - Chief Executive Officer, Chairman and Founder Fred Leffler - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH Capital Bruce Jackson - The Benchmark Company Operator Welcome to the Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions] Please note this event is being recorded.
Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $4.64 per share a year ago.
WOBURN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today reported financial results for the three and nine months ended September 30, 2024 and provided a business update.
WOBURN, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's sNDA to increase the maximally approved dosage from one to three tubes of Ameluz® per treatment.
Biofrontera Inc. (NASDAQ:BFRI ) Q2 2024 Earnings Conference Call August 15, 2024 10:00 AM ET Company Participants Andrew Barwicki - Barwicki Investor Relations Hermann Luebbert - CEO, Chairman and Founder Fred Leffler - CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Biofrontera Inc. Second Quarter 2024 Financial Results and Business Update Conference Call. All participants will be in a listen-only mode.
Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three and six months ended June 30, 2024 and provided a business update.
WOBURN, MA, June 24, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, is proud to announce the launch of its FDA-approved RhodoLED XL, a red light emitting LED lamp.
Biofrontera Inc. (NASDAQ: BFRI) Q1 2024 Earnings Conference Call will take place on May 16, 2024 at 10:00 AM ET. Company representatives include Andrew Barwicki, Hermann Luebbert, and Fred Leffler. Conference call participants include Jonathan Aschoff, Bruce Jackson, and others. Thank you for joining the Biofrontera Inc. First Quarter 2024 Financial Results and Business Update Conference Call. All participants are currently in listen-only mode.
Biofrontera Inc., a biopharmaceutical company focused on dermatological products, will release its financial results for the quarter ending March 29, 2024 on May 15, 2024 after the market closes. A conference call will be held on May 16 at 10:00am Eastern Time.
After losing some value lately, a hammer chart pattern has been formed for Biofrontera Inc. (BFRI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
What type of business is Biofrontera?
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
What sector is Biofrontera in?
Biofrontera is in the Healthcare sector
What industry is Biofrontera in?
Biofrontera is in the Drug Manufacturers - Specialty & Generic industry
What country is Biofrontera from?
Biofrontera is headquartered in United States
When did Biofrontera go public?
Biofrontera initial public offering (IPO) was on 29 October 2021
What is Biofrontera website?
https://www.biofrontera-us.com
Is Biofrontera in the S&P 500?
No, Biofrontera is not included in the S&P 500 index
Is Biofrontera in the NASDAQ 100?
No, Biofrontera is not included in the NASDAQ 100 index
Is Biofrontera in the Dow Jones?
No, Biofrontera is not included in the Dow Jones index
When was Biofrontera the previous earnings report?
No data
When does Biofrontera earnings report?
Next earnings report date is not announced yet